Business Context and Reporting Period
Ionis Pharmaceuticals, Inc. filed its Form 10-K for the fiscal year ended December 31, 2016. Ionis develops RNA-targeted antisense therapeutics through its Ionis Core segment and wholly owned Akcea Therapeutics subsidiary, which focuses on cardiometabolic and lipid-disorder medicines. SPINRAZA (nusinersen) received FDA approval in December 2016 for pediatric and adult spinal muscular atrophy, marking Ionis’s transition toward royalty and commercial revenue.
The filing reports annual results; fourth-quarter 2016 revenue was $160.3 million, operating income was $41.2 million, and net income was $25.9 million.
Financial Performance and Position
| Metric | 2016 | 2015 | Change |
|---|---|---|---|
| Total revenue | $346.6 million | $283.7 million | 22% |
| Research and development revenue | $325.9 million | $281.4 million | 16% |
| Licensing and royalty revenue | $20.7 million | $2.3 million | Material increase |
| Total operating expenses | $392.9 million | $359.5 million | 9% |
| Loss from operations | $(46.3) million | $(75.8) million | Improved |
| Net loss | $(86.6) million | $(88.3) million | Improved |
| Basic and diluted loss per share | $(0.72) | $(0.74) | Improved |
| Cash, cash equivalents and short-term investments | $665.2 million | $779.2 million | Down $114.0 million |
| Working capital | $664.1 million | $688.1 million | Down $24.0 million |
- Approximate operating margin was negative 13.4%, compared with negative 26.7% in 2015. Approximate net margin was negative 25.0%.
- Research, development and patent expense was $344.3 million, including $55.1 million of non-cash equity compensation. General and administrative expense was $48.6 million, including $17.0 million of non-cash equity compensation.
- Cash flow from operations was $(112.1) million, compared with $21.1 million provided in 2015. The primary working-capital drag was a $96.7 million increase in contracts receivable, together with a $59.2 million reduction in deferred contract revenue.
- Investing activities provided $56.6 million, primarily reflecting net sales and maturities of short-term investments. Capital expenditures were $7.1 million.
- Financing activities provided $11.4 million, including $12.6 million from equity issuances and $4.0 million of borrowings under the credit facility, partly offset by $7.1 million of debt and capital-lease payments.
- Debt and other obligations totaled $774.1 million at year-end. The company reported $685.5 million principal amount of 1% convertible senior notes due 2021, with an approximately $66.81 conversion price and potential conversion into approximately 10.3 million shares. It also had $12.5 million outstanding under a $30 million revolving credit facility.
- Stockholders’ equity was $99.6 million, down from $200.8 million, and accumulated deficit was $1.181 billion. The company has never paid dividends and does not anticipate doing so in the foreseeable future.
Material Changes Versus the Prior Comparable Period
- Revenue increased primarily because of $170 million received from Biogen for SPINRAZA FDA approval, licensing and advancement of the Phase 3 program. Biogen also became responsible for future global development, regulatory and commercialization costs.
- Ionis recognized $98 million of research and development revenue from license fees associated with partner option exercises, including transactions involving AstraZeneca, Biogen and Janssen.
- 2016 revenue included $53 million from AstraZeneca, $15 million from Janssen, $15 million from Kastle for Kynamro rights, and $7.5 million from Biogen for additional neurological programs.
- Operating expenses increased as SPINRAZA, volanesorsen and IONIS-TTR Rx advanced through expensive late-stage clinical programs and Akcea built commercial infrastructure. Akcea operating expenses, excluding non-cash compensation, increased to $73.4 million from $46.3 million.
- Ionis completed a December 2016 debt exchange, issuing $185.5 million of 1% convertible notes in exchange for $61.1 million principal amount of 2.75% notes. The transaction extended maturities and kept expected cash interest expense broadly flat, but produced a $4.0 million non-cash loss on early debt retirement.
- Fourth-quarter results shifted to profitability because of unusually high collaboration and licensing revenue: Q4 revenue was $160.3 million versus $51.6 million in Q4 2015.
Guidance, Outlook, Commentary, Risks and Unusual Items
- Management planned to report Phase 3 APPROACH data for volanesorsen in the first quarter of 2017 and Phase 3 NEURO-TTR data for IONIS-TTR Rx in the second quarter of 2017. If results were positive, the company planned regulatory filings for volanesorsen in the United States, Europe and Canada and filings for IONIS-TTR Rx with GSK.
- Management expected Akcea costs to continue increasing in 2017 as it builds commercialization capabilities for volanesorsen. The filing also disclosed a January 2017 Novartis collaboration for AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx, including a $75 million upfront payment, a $100 million Ionis equity investment by Novartis, and an additional potential $50 million equity investment.
- The company reported positive COMPASS results for volanesorsen, including a statistically significant 71% mean triglyceride reduction, but identified platelet monitoring and severe thrombocytopenia as important potential commercial and regulatory risks.
- Ionis remains dependent on collaboration and licensing payments, with 60% of 2016 revenue derived from Biogen and 19% from AstraZeneca. Timing and amount of revenue can vary substantially based on partner milestones, option exercises and licensing activity.
- Key risks include clinical-trial failure or delay, regulatory non-approval, adverse safety findings, reimbursement and market acceptance, competition from alternative RNA therapies and gene therapies, manufacturing constraints, partner termination or underperformance, patent challenges, and dependence on key personnel.
- The company had an accumulated deficit of approximately $1.2 billion, continued to incur operating losses, and stated that additional funding could be required if commercialization and partnering objectives are not achieved.
- Ionis and Merck are pursuing an appeal in the Gilead patent litigation involving sofosbuvir. A jury upheld asserted patent claims and awarded damages based on past sales, but the trial judge ruled the patents unenforceable under the doctrine of unclean hands; the appeal was pending at filing.
- Ernst & Young issued an unqualified audit opinion on the financial statements and internal control over financial reporting. Management concluded that disclosure controls and internal controls were effective as of December 31, 2016.
Most Important Facts for an Investor to Verify
- Whether SPINRAZA royalties and international approvals develop into recurring commercial revenue rather than primarily one-time licensing and milestone revenue.
- Final Phase 3 efficacy and safety results, regulatory filings, and approval prospects for volanesorsen and IONIS-TTR Rx, particularly platelet-related safety and monitoring requirements.
- Cash burn, collection of contracts receivable, remaining deferred revenue, and the adequacy of $665.2 million in cash and investments relative to planned clinical and Akcea spending.
- Debt maturity and dilution exposure from the $685.5 million principal amount of 1% convertible notes and their potential conversion into approximately 10.3 million shares.
- Revenue concentration and termination provisions in the Biogen, AstraZeneca, GSK, Bayer, Janssen, Roche and Novartis agreements.
- The outcome and potential economic impact of the Gilead patent appeal.
- The filing text does not provide a clear consolidated adjusted EBITDA or free-cash-flow measure; investors should reconcile any non-GAAP measures separately.